Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts

Nenhuma Miniatura disponível
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BENTHAM SCIENCE PUBL LTD
Autores
MASCHIO-SIGNORINI, Larissa B.
GELALETI, Gabriela B.
MOSCHETTA, Marina G.
BORIN, Thaiz F.
JARDIM-PERASSI, Bruna V.
LOPES, Juliana R.
LACERDA, Jessica Z.
BORDIN, Newton A.
CORREA, Lizandra A.
Citação
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, v.16, n.11, p.1474-1484, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Cancer-associated fibroblast (CAFs) are the most abundant cells in the tumor microenvironment, able to secrete growth factors and act on tumor progression. Melatonin is associated with several mechanisms of action with oncostatics and oncoprotectors effects, and also participate in the reduction of synthesis of surrounding fibroblasts and endothelial cells in breast cancer. Objective: The objectives of this study were to determine the effectiveness of melatonin in cell viability and expression of proteins involved in angiogenesis and inflammation in triplenegative mammary tumor cell line (MDA-MB-231) and in co-culture with CAFs. Method: Cell viability was measured by MTT assay and the protein expression was evaluated by Membrane Antibody Array after melatonin treatment. Results: Melatonin treatment (1 mM) for 48 hours reduced the cell viability of MDA-MB-231, CAFs and co-culture (p < 0.05). The semi-quantitative protein analysis showed that when monoculture of tumor cells were compared with co-culture of CAFs, there was a regulation of angiogenic and inflammatory proteins (p < 0.05). Melatonin treatment also leads a differential expression of angiogenic and inflammatory proteins in both monoculture and co-culture of tumor cells and CAFs (p < 0.05). Conclusion: The influence of CAFs under the tumor microenvironment was confirmed, increasing the malignancy of the tumor. In addition, melatonin is effective in both monoculture and co-culture, regulating angiogenic and inflammatory proteins that contribute to tumor progression. This study show an overview of melatonin ability in regulating angiogenic and inflammatory proteins, and opens the way for exploration of each individual protein in further studies.
Palavras-chave
Breast cancer, melatonin, microenvironment, angiogenesis, inflammation, co-culture
URI
https://observatorio.fm.usp.br/handle/OPI/17874
Referências
  1. Adjei Isaac M, 2015, J Funct Biomater, V6, P81, DOI 10.3390/jfb6010081
  2. Alvarez-Garcia V, 2012, J PINEAL RES, V52, P282, DOI 10.1111/j.1600-079X.2011.00940.x
  3. Apostolopoulou M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033289
  4. Borin TF, 2016, J PINEAL RES, V60, P3, DOI 10.1111/jpi.12270
  5. Brunckhorst MK, 2014, AM J PATHOL, V184, P2285, DOI 10.1016/j.ajpath.2014.05.006
  6. Carrillo-Vico A, 2013, INT J MOL SCI, V14, P8638, DOI 10.3390/ijms14048638
  7. Dentelli P, 2011, ONCOGENE, V30, P4930, DOI 10.1038/onc.2011.204
  8. Di Bella G, 2013, INT J MOL SCI, V14, P2410, DOI 10.3390/ijms14022410
  9. Garcia-Maurino S, 1999, LIFE SCI, V65, P2143, DOI 10.1016/S0024-3205(99)00479-8
  10. Gelaleti GB, 2012, VET IMMUNOL IMMUNOP, V146, P106, DOI 10.1016/j.vetimm.2012.02.005
  11. Han N, 2015, ONCOTARGET, V6, P5877
  12. Ishikawa Mami, 2014, Cancers (Basel), V6, P1570, DOI 10.3390/cancers6031570
  13. Jardim-Perassi BV, 2016, ANTI-CANCER AGENT ME, V16, P347, DOI 10.2174/1871520615666150511094201
  14. Jardim-Perassi BV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085311
  15. Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
  16. Kato T, 2011, EXP DERMATOL, V20, P669, DOI 10.1111/j.1600-0625.2011.01286.x
  17. Kim JY, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-82
  18. Knower KC, 2012, BREAST CANCER RES TR, V132, P765, DOI 10.1007/s10549-012-1953-4
  19. Korkmaz A, 2012, GENE, V503, P1, DOI 10.1016/j.gene.2012.04.040
  20. Le Bitoux MA, 2008, HISTOCHEM CELL BIOL, V130, P1079, DOI 10.1007/s00418-008-0527-3
  21. Lee EJ, 2013, CELL SIGNAL, V25, P2025, DOI 10.1016/j.cellsig.2013.06.004
  22. Levashova Z, 2010, J NUCL MED, V51, P959, DOI 10.2967/jnumed.109.072199
  23. Li JH, 2008, SAUDI MED J, V29, P1088
  24. Lim JB, 2014, CANCER SCI, V105, P1327, DOI 10.1111/cas.12505
  25. Luker KE, 2012, ONCOGENE, V31, P4750, DOI 10.1038/onc.2011.633
  26. Lyon DE, 2008, NURS RES, V57, P51
  27. Mestroni Luisa, 1998, Cardiology Clinics, V16, P611, DOI 10.1016/S0733-8651(05)70038-2
  28. Min AJ, 2015, J BIOCHEM MOL TOXIC, V29, P70, DOI 10.1002/jbt.21669
  29. Okabe H, 2012, INT J CANCER, V131, P2234, DOI 10.1002/ijc.27496
  30. Ordonez R, 2014, J PINEAL RES, V56, P20, DOI 10.1111/jpi.12092
  31. Peng Li, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1421
  32. Porretti JC, 2014, INT J BIOCHEM CELL B, V51, P29, DOI 10.1016/j.biocel.2014.03.016
  33. Rozenchan PB, 2009, INT J CANCER, V125, P2767, DOI 10.1002/ijc.24646
  34. Rudra DS, 2013, J PINEAL RES, V54, P398, DOI 10.1111/jpi.12034
  35. Sadras T, 2014, J LEUKOCYTE BIOL, V96, P83, DOI 10.1189/jlb.2AB1013-559R
  36. Saleh M, 1997, INT J CANCER, V72, P664, DOI 10.1002/(SICI)1097-0215(19970807)72:4<664::AID-IJC19>3.0.CO;2-B
  37. Shalamzari SA, 2014, IRAN J BASIC MED SCI, V17, P231
  38. Slattery ML, 2014, CARCINOGENESIS, V35, P1750, DOI 10.1093/carcin/bgu078
  39. Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018
  40. Srinivasan Venkatramanujam, 2011, Recent Pat Endocr Metab Immune Drug Discov, V5, P109
  41. Tabata C, 2010, EUR RESPIR J, V36, P1099, DOI 10.1183/09031936.00154009
  42. Talib WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124384
  43. Torres S, 2013, CLIN CANCER RES, V19, P6006, DOI 10.1158/1078-0432.CCR-13-1130
  44. Wendt M. K., 2014, JAKSTAT, V3, DOI 10.4161/JKST.28975
  45. Xia JL, 2015, EXPERT OPIN THER TAR, V19, P141, DOI 10.1517/14728222.2014.993317
  46. Yao Y, 2014, J IMMUNOL METHODS, V415, P1, DOI 10.1016/j.jim.2014.10.010
  47. Yuan L, 2002, MOL CELL ENDOCRINOL, V192, P147, DOI 10.1016/S0303-7207(02)00029-1
  48. Zaynagetdinov R, 2015, CANCER RES, V75, P1624, DOI 10.1158/0008-5472.CAN-14-2379
  49. Zhang J, 2013, PHARMACOL THERAPEUT, V137, P200, DOI 10.1016/j.pharmthera.2012.10.003
  50. Zhu Li-Li, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P847

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03